Dolutegravir use over 48 weeks is not associated with worsening insulin resistance and pancreatic beta cell function in a cohort of HIV-infected Ugandan adults

Mostrar otras versiones (1)

BACKGROUND: The Uganda Ministry of Health issued restrictive guidelines on the use of dolutegravir (DTG) in persons stratified to have a heightened risk of diabetes mellitus. This followed multiple reports of persons with HIV (PWH) presenting with accelerated hyperglycemia after a few weeks to month...

Descripción completa

Detalles Bibliográficos
Autores principales: Mulindwa, Frank, Castelnuovo, Barbara, Brusselaers, Nele, Nabwana, Martin, Bollinger, Robert, Buzibye, Allan, Agnes Odongpiny, Eva Laker, Kiguba, Ronald, Schwarz, Jean-Marc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10492310/
https://www.ncbi.nlm.nih.gov/pubmed/37689695
http://dx.doi.org/10.1186/s12981-023-00564-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10492310/
https://www.ncbi.nlm.nih.gov/pubmed/37689695
http://dx.doi.org/10.1186/s12981-023-00564-6

Ejemplares similares